Late last year, Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), developed compelling data in an asthma model and is now ramping up that program.
In October 2016, Cynata announced it had received convincing data from a proof of concept study of its Cymerus™ iPSC-derived mesenchymal stem cells (MSCs) in an experimental model of asthma. Those initial results demonstrated that Cymerus™ MSCs can exert a powerful effect via improved airway hyper-responsiveness. [Read more…]